Jeffrey A. Bluestone

The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.

The Src family kinase Fyn mediates signals induced by TCR antagonists.

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.

Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.

The immune tolerance network: a new paradigm for developing tolerance-inducing therapies.

Inability to induce tolerance through direct antigen presentation.

Immunotherapy of insulin-dependent diabetes mellitus.

Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.

When ligand becomes receptor--tolerance via B7 signaling on DCs.

Negative regulation of T cell receptor-lipid raft interaction by cytotoxic T lymphocyte-associated antigen 4.

CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment.

Impairment of NK cell function by NKG2D modulation in NOD mice.

CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo.

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

Natural versus adaptive regulatory T cells.

Directed evolution of a single-chain class II MHC product by yeast display.

Altered cutaneous immune parameters in transgenic mice overexpressing viral IL-10 in the epidermis.

Clinical trials of transplant tolerance: slow but steady progress.

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes.

Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.

Peptide-MHC class II dimers as therapeutics to modulate antigen-specific T cell responses in autoimmune diabetes.

The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells.

CTLA-4 and tolerance: the biochemical point of view.

Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.

Beta-cell replacement for type I diabetes.

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.

CTLA-4: acting at the synapse.

Notch 1 signaling regulates peripheral T cell activation.

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

CTLA-4 regulates expansion and differentiation of Th1 cells following induction of peripheral T cell tolerance.

NKG2D blockade prevents autoimmune diabetes in NOD mice.

Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells.

Peptide specific amelioration of T cell mediated pathogenesis in murine type 1 diabetes.

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells.

Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function.

CTLA-4Ig is finally making it: a personal perspective.

The NOD mouse: a model of immune dysregulation.

Regulatory T-cell therapy: is it ready for the clinic?

Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis.

Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo.

An important role of CD80/CD86-CTLA-4 signaling during photocarcinogenesis in mice.

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.

B7-independent inhibition of T cells by CTLA-4.

A comprehensive review of interventions in the NOD mouse and implications for translation.

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.

A peptide of glutamic acid decarboxylase 65 can recruit and expand a diabetogenic T cell clone, BDC2.5, in the pancreas.

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

How do CD4+CD25+ regulatory T cells control autoimmunity?

Distinct effector mechanisms in the development of autoimmune neuropathy versus diabetes in nonobese diabetic mice.

Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.

Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice.

Achieving antigen-specific tolerance in diabetes: regulating specifically.

Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential.

CTLA4Ig: bridging the basic immunology with clinical application.

Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs.

Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship?

CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells.

Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.

Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist.

Regulatory T-cell physiology and application to treat autoimmunity.

Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Sensory neurons link the nervous system and autoimmune diabetes.

Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment.

Expression of CTLA-4 and FOXP3 in cis protects from lethal lymphoproliferative disease.

Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus.

Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse.

Mechanisms of PDL1-mediated regulation of autoimmune diabetes.

CD3-specific antibodies: a portal to the treatment of autoimmunity.

What does the future hold for cell-based tolerogenic therapy?

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

对树突状细胞整合素 α (v) beta8 损失导致小鼠自身免疫和结肠炎。

B cell depletion: a novel therapy for autoimmune diabetes?

Regulated beta-cell regeneration in the adult mouse pancreas.

Safer, longer-lasting regulatory T cells with beta-catenin.

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation.

CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells.

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.

Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice.

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities.

T regulatory cells in autoimmune diabetes: past challenges, future prospects.

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity.

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.

Expansion of human regulatory T-cells from patients with type 1 diabetes.

The role of X-linked FOXP3 in the autoimmune susceptibility of Turner Syndrome patients.

A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Plasticity of CD4(+) FoxP3(+) T cells.

T-bet-deficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function.

Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome.

Insulin receptor substrate-2 in beta-cells decreases diabetes in nonobese diabetic mice.

Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Regulatory T cells as therapeutic targets in rheumatoid arthritis.

The functional plasticity of T cell subsets.

Is antigen specificity of autoreactive T cells the key to islet entry?

Autoimmunity.

Regulatory T cells directed to the site of the action.

Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.

Ten years of the Immune Tolerance Network: an integrated clinical research organization.

Small RNA regulators of T cell-mediated autoimmunity.

Suppression of human anti-porcine natural killer cell xenogeneic responses by combinations of monoclonal antibodies specific to CD2 and NKG2D and extracellular signal-regulated kinase kinase inhibitor.

Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia.

Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

FK506 causes cellular and functional defects in human natural killer cells.

Clusterin synergizes with IL-2 for the expansion and IFN-γ production of natural killer cells.

The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade.

Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice.

Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells.

Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice.

Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes.

Mechanisms of tolerance.

Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.

How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited.

Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts.

Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice.

Regulatory T cells: stability revisited.

Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.

Control of TH17 cells occurs in the small intestine.

Type 1 diabetes immunotherapy: is the glass half empty or half full?

Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation.

Pillars article: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994. 1: 405-413.

A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse.

The yin and yang of interleukin-2-mediated immunotherapy.

CD4+Foxp3+ regulatory T cell therapy in transplantation.